Latest News

BerGenBio plans IPO and partners with MSD

To activate the Axl kinase and transmit its signal to the cell nucleus, the GAS6 ligand has to bind externally and the energy carrier ATP (green) internally. Inhibitors (orange) prevent transmission of the signal, © MPI for Biochemistry


by tg

Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.

The IPO, underwritten by ABG Sundal Collier, Arctic Securities and DNB Markets, includes a public offering to institutional and retail investors in Norway and Sweden, and a private placement to certain institutional investors internationally.

BerGenBio’s lead candidate BGB324 (formerly R-428), licensed from Rigel Pharmaceuticals in 2010, has passed Phase Ib testing in acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), and non-small cell lung cancer (NSCLC, in combination with erlonitib) patients. On the day of the IPO announcement, BerGenBio additionally said it will start two collaborative Phase II combination studies of BGB324 with Merck & Co’s PD-1 checkpoint inhibitor pembrolizumab this year in patients with adenocarcinoma (NSCLC) and and triple-negative breast cancer (TNBC). The clinical trials will be sponsored by BerGenBio while Merck will provide the trial with Keytruda. The rights to the study results will be shared. Financial details were not disclosed. Preclinical data from 2015 indicate that BGB324 showed enhanced tumour clearance, survival and tumour infiltration of cytotoxic T lymphocytes compared with checkpoint inhibition (CTLA-4, PD1) alone.

Axl kinase promotes cancer cell migration, epithelial-mesenchymal transition (EMT) and tumour cell proliferation as well as therapy resistance. The protein is overexpressed in the membranes of 60% of lung cancers, highly invasive breast cancers, and pancreatic cancer as well as in AML, where it serves as independent prognostic marker. Additionally, several studies suggest that overexpression of AXL may result in resistance to both targeted therapies and conventional chemotherapy in different models, such as lung cancer, breast cancer resistant to EGFR inhibition, esophageal carcinoma, gastrointestinal stromal tumours, and AML. 

Besides its selective Axl kinase inhibitor, the Norwegian company also has an anti-Axl kinase antibody and an antibody drug conjugate (ADC) under preclinical development. Treatment responders are set to be stratified prior to therapy by a companion diagnostics test that measures Axl kinase expression.

ADC Therapeutics enters licence option deal with Avacta Group

Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to undisclosed cancer...

Gut bacterial enzyme keeps inflammation away

In studies in human cells, Victor Duarte and colleagues from University of Grenoble, found broad-spectrum antimicrobial activity of a compound...

3P Pharma finds new major investor

Healx Ltd raises $56m in Series B financing

The financing was led by Atomico and joined by Intel Capital, Global Brain and btov Partners as new investors. Existing investors from a US$10m...

Spanish sector attracting more and more investment

According to Spain's biotech association, the investor day attracted 60 investors from nine countries and provided more than 500 partnering...

Araris Biotech AG kicks-off with CHF2.5m seed financing

The company said it will use the proceeds to develop a pipeline of antibody-drug conjugates (ADCs). However, its platform can be also used to...

Researchers unravel how ADEP antibiotics work

Fighting antimicrobial resistance has been named one of the prioritary goals by the World Health Organization (WHO). However, as the number of...